Empowered Funds LLC Invests $1.50 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Empowered Funds LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,426 shares of the specialty pharmaceutical company's stock, valued at approximately $1,498,000. Empowered Funds LLC owned about 0.08% of Supernus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SUPN. GAMMA Investing LLC boosted its stake in shares of Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 398 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after acquiring an additional 352 shares during the period. KBC Group NV boosted its position in Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after purchasing an additional 929 shares in the last quarter. Kennebec Savings Bank acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $103,000. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $211,000.

Insider Activity

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Price Performance

SUPN stock traded down $6.27 during mid-day trading on Wednesday, reaching $33.48. 2,048,291 shares of the company's stock were exchanged, compared to its average volume of 408,736. The company has a market cap of $1.85 billion, a price-to-earnings ratio of 31.29 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The stock's 50 day moving average is $37.64 and its 200 day moving average is $35.28.

Analyst Ratings Changes

Separately, Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $57.00 to $36.00 in a report on Wednesday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.